Hoth Therapeutics (HOTH)
(Delayed Data from NSDQ)
$1.17 USD
0.00 (0.00%)
Updated Apr 25, 2024 03:56 PM ET
After-Market: $1.11 -0.06 (-5.13%) 6:06 PM ET
2-Buy of 5 2
D Value D Growth C Momentum D VGM
Price, Consensus and EPS Surprise
HOTH 1.17 0.00(0.00%)
Will HOTH be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for HOTH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HOTH
Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data
HOTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for HOTH
Hoth Therapeutics files to sell 5.03M shares of common stock for holders
Hoth Therapeutics files to sell 5.03M shares of common stock for holders
Promising Preclinical Alzheimer’s Candidate and Diverse Pipeline Bolster Hoth Therapeutics’ Buy Rating
Hoth Therapeutics price target raised by 50c at EF Hutton, here's why
Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds